NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Phase 1

Active, not recruiting

Conditions: Recurrent Malignant Solid Neoplasm
Refractory Alveolar Rhabdomyosarcoma
Refractory Ewing Sarcoma
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Recurrent Alveolar Rhabdomyosarcoma
Recurrent Ewing Sarcoma
Recurrent Lymphoma

Interventions: Drug: Elimusertib

First Posted Date: 2021-10-08

Last Posted Date: 2025-02-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT05071209

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 26 locations

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Phase 2

Active, not recruiting

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Metastatic Lip and Oral Cavity Carcinoma
Metastatic Nasal Cavity Squamous Cell Carcinoma
Metastatic Nasopharyngeal Squamous Cell Carcinoma
Metastatic Pharyngeal Squamous Cell Carcinoma
Metastatic Sinonasal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Biological: Bevacizumab
Biological: Atezolizumab
Drug: Carboplatin
Biological: Cetuximab
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-10-01

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 430

Registration Number: NCT05063552

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Epic Care-Dublin, Dublin, California, United States
🇺🇸
Epic Care Partners in Cancer Care, Emeryville, California, United States

and more 169 locations

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Phase 2

Recruiting

Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma
Metastatic Extrapulmonary Neuroendocrine Carcinoma
Recurrent Extrapulmonary Neuroendocrine Carcinoma
Unresectable Extrapulmonary Neuroendocrine Carcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Etoposide
Procedure: Magnetic Resonance Imaging
Other: Patient Observation

First Posted Date: 2021-09-28

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 189

Registration Number: NCT05058651

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 212 locations

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

Phase 1

Recruiting

Conditions: Advanced Pancreatic Carcinoma
B-Cell Non-Hodgkin Lymphoma
Metastatic Pancreatic Carcinoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Lymphoma
Stage II Pancreatic Cancer AJCC v8
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory T-Cell Non-Hodgkin Lymphoma
Refractory Pancreatic Carcinoma

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Core Biopsy
Drug: Entinostat

First Posted Date: 2021-09-23

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05053971

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

Recruiting

Conditions: COVID-19

First Posted Date: 2021-09-16

Last Posted Date: 2025-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 177

Registration Number: NCT05044780

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
INOVA Fairfax Medical Campus, Fairfax, Virginia, United States

Evaluation of Patients With Gastrointestinal Disease

Recruiting

Conditions: Gastrointestinal Diseases
Lower GI Disease

First Posted Date: 2021-09-13

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 4000

Registration Number: NCT05041374

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1

Recruiting

Conditions: Kita-kyushu Lung Cancer Antigen 1, Human

Interventions: Drug: IL-2 (Aldesleukin)
Drug: Cyclophosphamide
Biological: KK-LC-1 TCR
Drug: Fludarabine

First Posted Date: 2021-09-05

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT05035407

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Phase 2

Recruiting

Conditions: Immunodeficiency
Hematopoietic Stem Cell Transplantation

Interventions: Procedure: Allogeneic HSCT
Drug: Busulfan test dose
Drug: Mycophenolate mofetil (MMF)
Drug: Tacrolimus
Drug: Busulfan
Radiation: Total Body Irradiation (TBI)
Drug: Fludarabine
Drug: Post-Transplant Cyclophosphamide (PTCY)
Drug: Cyclophosphamide (CY)

First Posted Date: 2021-08-31

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT05027945

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1

Recruiting

Conditions: Advanced NUT Carcinoma
Unresectable NUT Carcinoma
Metastatic NUT Carcinoma

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Chest Radiography
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Etoposide
Procedure: FDG-Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-08-25

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT05019716

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 2 locations

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Phase 2

Completed

Conditions: Neoplasm of the Nasal Cavity
Olfactory Neuroblastoma
Esthesioneuroblastoma

Interventions: Drug: Bintrafusp alfa / M7824

First Posted Date: 2021-08-19

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT05012098

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy